MBRX

Moleculin is a pre-revenue, late-stage oncology developer whose entire value rests on Annamycin (naxtarubicin) in the pivotal Phase 3 MIRACLE trial for relapsed/refractory AML. Five straight years of zero revenue and a widening loss (net income -$33.6M in FY2025, down 28.8% YoY) leave no operating business underneath the stock — only a clinical option. The accumulated deficit of -$206M and ROE of -223.6% quantify how much shareholder capital this program has already consumed, and the FY2025 share count of just 5.34M (down 61.9% YoY) is the fingerprint of a reverse split layered on top of chronic equity issuance — i.e., prior holders have been repeatedly diluted and optically reset.

The dominant, near-certain fact is the funding cliff. FY2025 operating cash flow was -$22.7M against only $8.88M of cash and equivalents. That is well under five months of runway at the current burn — the company must raise capital, almost certainly through dilutive equity at or below $2.64, and likely before or right into the mid-2026 interim unblinding it is touting as a catalyst. A financing overhang of this magnitude tends to cap any pre-data run and amplifies downside if the readout disappoints. The balance sheet is otherwise unremarkable (liabilities/equity 0.47x, no debt stress), but $15.0M of equity is small and shrinking in economic terms as losses accrete.